JP2012522748A

JP2012522748A - ステアロイル−ｃｏａデサチュラーゼ調節用スピロ誘導体

ステアロイル−ｃｏａデサチュラーゼ調節用スピロ誘導体 Download PDF

Info

Publication number: JP2012522748A
Authority: JP; Japan
Prior art keywords: alkyl; piperidine; cycloalkyl; carboxamide; pyridin
Prior art date: 2009-04-01
Legal status : Withdrawn

Application number

JP2012502648A

Other languages

English (en)

Japanese (ja)

Other versions

JP2012522748A5 (enExample

Inventor

ナタリー・デールス

ジュリア・フォナレブ

ジャンミン・フ

ザイフイ・チャン

Current Assignee

Xenon Pharmaceuticals Inc

Original Assignee

Xenon Pharmaceuticals Inc

Priority date

2009-04-01

Filing date

2010-03-30

Publication date

2012-09-27

2010-03-30 Application filed by Xenon Pharmaceuticals Inc filed Critical Xenon Pharmaceuticals Inc

2012-09-27 Publication of JP2012522748A publication Critical patent/JP2012522748A/ja

2013-05-16 Publication of JP2012522748A5 publication Critical patent/JP2012522748A5/ja

Status Withdrawn legal-status Critical Current

Links

125000003003 spiro group Chemical group 0.000 title abstract description 4
108010087894 Fatty acid desaturases Proteins 0.000 claims abstract description 88
238000000034 method Methods 0.000 claims abstract description 83
230000000694 effects Effects 0.000 claims abstract description 43
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 28
102000016553 Stearoyl-CoA Desaturase Human genes 0.000 claims abstract 6
150000001875 compounds Chemical class 0.000 claims description 276
-1 cyano, hydroxy Chemical group 0.000 claims description 160
125000000753 cycloalkyl group Chemical group 0.000 claims description 104
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 103
125000003118 aryl group Chemical group 0.000 claims description 86
125000000623 heterocyclic group Chemical group 0.000 claims description 86
125000001072 heteroaryl group Chemical group 0.000 claims description 84
125000000217 alkyl group Chemical group 0.000 claims description 83
201000010099 disease Diseases 0.000 claims description 80
125000003710 aryl alkyl group Chemical group 0.000 claims description 68
239000001257 hydrogen Substances 0.000 claims description 64
229910052739 hydrogen Inorganic materials 0.000 claims description 64
125000005843 halogen group Chemical group 0.000 claims description 55
125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 53
238000004519 manufacturing process Methods 0.000 claims description 50
150000003839 salts Chemical class 0.000 claims description 47
125000001188 haloalkyl group Chemical group 0.000 claims description 44
125000004446 heteroarylalkyl group Chemical group 0.000 claims description 44
150000002431 hydrogen Chemical class 0.000 claims description 42
125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 38
125000004432 carbon atom Chemical group C* 0.000 claims description 35
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 33
230000001404 mediated effect Effects 0.000 claims description 28
125000003342 alkenyl group Chemical group 0.000 claims description 26
125000003545 alkoxy group Chemical group 0.000 claims description 25
125000002768 hydroxyalkyl group Chemical group 0.000 claims description 24
208000035475 disorder Diseases 0.000 claims description 23
SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims description 23
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 23
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 22
125000004183 alkoxy alkyl group Chemical group 0.000 claims description 22
239000003814 drug Substances 0.000 claims description 22
239000003112 inhibitor Substances 0.000 claims description 21
208000008589 Obesity Diseases 0.000 claims description 19
125000000304 alkynyl group Chemical group 0.000 claims description 19
229910052799 carbon Inorganic materials 0.000 claims description 19
235000020824 obesity Nutrition 0.000 claims description 19
125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 19
241000124008 Mammalia Species 0.000 claims description 18
208000017170 Lipid metabolism disease Diseases 0.000 claims description 16
125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 11
125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 11
208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 11
208000032928 Dyslipidaemia Diseases 0.000 claims description 10
208000001145 Metabolic Syndrome Diseases 0.000 claims description 10
201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 10
239000003937 drug carrier Substances 0.000 claims description 10
230000005764 inhibitory process Effects 0.000 claims description 10
239000000546 pharmaceutical excipient Substances 0.000 claims description 10
PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 9
125000004093 cyano group Chemical group *C#N 0.000 claims description 9
206010012601 diabetes mellitus Diseases 0.000 claims description 9
125000004438 haloalkoxy group Chemical group 0.000 claims description 8
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 7
230000002401 inhibitory effect Effects 0.000 claims description 7
239000003446 ligand Substances 0.000 claims description 7
125000003367 polycyclic group Chemical group 0.000 claims description 7
208000017520 skin disease Diseases 0.000 claims description 7
DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims description 6
206010022489 Insulin Resistance Diseases 0.000 claims description 6
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 6
208000011580 syndromic disease Diseases 0.000 claims description 6
101000631826 Homo sapiens Stearoyl-CoA desaturase Proteins 0.000 claims description 5
102000055981 human SCD1 Human genes 0.000 claims description 5
239000011664 nicotinic acid Substances 0.000 claims description 5
235000001968 nicotinic acid Nutrition 0.000 claims description 5
230000002829 reductive effect Effects 0.000 claims description 5
CEPSJAIIFPRILD-UHFFFAOYSA-N 7-fluoro-n-[4-(methylcarbamoyl)pyridin-2-yl]-4-oxospiro[3h-chromene-2,4'-piperidine]-1'-carboxamide Chemical compound CNC(=O)C1=CC=NC(NC(=O)N2CCC3(CC2)OC2=CC(F)=CC=C2C(=O)C3)=C1 CEPSJAIIFPRILD-UHFFFAOYSA-N 0.000 claims description 4
208000002874 Acne Vulgaris Diseases 0.000 claims description 4
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 4
206010000496 acne Diseases 0.000 claims description 4
125000001153 fluoro group Chemical group F* 0.000 claims description 4
229960003512 nicotinic acid Drugs 0.000 claims description 4
230000002265 prevention Effects 0.000 claims description 4
DVDORZHPBMOJAU-UHFFFAOYSA-N 6-fluoro-n-[4-[(5-methyl-1,2-oxazol-3-yl)methylcarbamoyl]pyridin-2-yl]spiro[3,4-dihydrochromene-2,4'-piperidine]-1'-carboxamide Chemical compound O1C(C)=CC(CNC(=O)C=2C=C(NC(=O)N3CCC4(CC3)OC3=CC=C(F)C=C3CC4)N=CC=2)=N1 DVDORZHPBMOJAU-UHFFFAOYSA-N 0.000 claims description 3
RZAAQIJYIQVPLL-UHFFFAOYSA-N 8-chloro-n-[4-(methylcarbamoyl)pyridin-2-yl]-4-oxospiro[3h-chromene-2,4'-piperidine]-1'-carboxamide Chemical compound CNC(=O)C1=CC=NC(NC(=O)N2CCC3(CC2)OC2=C(Cl)C=CC=C2C(=O)C3)=C1 RZAAQIJYIQVPLL-UHFFFAOYSA-N 0.000 claims description 3
XSOMTMVYQGTMOC-UHFFFAOYSA-N 8-chloro-n-[4-(methylcarbamoyl)pyridin-2-yl]spiro[3,4-dihydrochromene-2,4'-piperidine]-1'-carboxamide Chemical compound CNC(=O)C1=CC=NC(NC(=O)N2CCC3(CC2)OC2=C(Cl)C=CC=C2CC3)=C1 XSOMTMVYQGTMOC-UHFFFAOYSA-N 0.000 claims description 3
208000030814 Eating disease Diseases 0.000 claims description 3
208000019454 Feeding and Eating disease Diseases 0.000 claims description 3
206010020772 Hypertension Diseases 0.000 claims description 3
206010023330 Keloid scar Diseases 0.000 claims description 3
206010027525 Microalbuminuria Diseases 0.000 claims description 3
102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 claims description 3
108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 claims description 3
125000001309 chloro group Chemical group Cl* 0.000 claims description 3
235000014632 disordered eating Nutrition 0.000 claims description 3
239000008103 glucose Substances 0.000 claims description 3
IHROGSPCAYGOHJ-UHFFFAOYSA-N n-(4-carbamoylpyridin-2-yl)-6-fluorospiro[3,4-dihydrochromene-2,4'-piperidine]-1'-carboxamide Chemical compound NC(=O)C1=CC=NC(NC(=O)N2CCC3(CC2)OC2=CC=C(F)C=C2CC3)=C1 IHROGSPCAYGOHJ-UHFFFAOYSA-N 0.000 claims description 3
GPPQSKJCIMSNHA-UHFFFAOYSA-N n-[4-(methylcarbamoyl)pyridin-2-yl]spiro[1,3-dihydroindene-2,4'-piperidine]-1'-carboxamide Chemical compound CNC(=O)C1=CC=NC(NC(=O)N2CCC3(CC4=CC=CC=C4C3)CC2)=C1 GPPQSKJCIMSNHA-UHFFFAOYSA-N 0.000 claims description 3
230000036573 scar formation Effects 0.000 claims description 3
201000005665 thrombophilia Diseases 0.000 claims description 3
YUQNMSHQHNXGBK-UHFFFAOYSA-N 4-chloro-n-[4-(methylcarbamoyl)pyridin-2-yl]spiro[1,3-dihydroindene-2,4'-piperidine]-1'-carboxamide Chemical compound CNC(=O)C1=CC=NC(NC(=O)N2CCC3(CC4=C(Cl)C=CC=C4C3)CC2)=C1 YUQNMSHQHNXGBK-UHFFFAOYSA-N 0.000 claims description 2
KUGGGESSHFFBEL-UHFFFAOYSA-N 5-chloro-n-[4-(methylcarbamoyl)pyridin-2-yl]spiro[2,4-dihydro-1h-naphthalene-3,4'-piperidine]-1'-carboxamide Chemical compound CNC(=O)C1=CC=NC(NC(=O)N2CCC3(CC2)CC2=C(Cl)C=CC=C2CC3)=C1 KUGGGESSHFFBEL-UHFFFAOYSA-N 0.000 claims description 2
PHYZSAULJWQSEQ-UHFFFAOYSA-N 5-fluoro-n-[4-(methylcarbamoyl)pyridin-2-yl]spiro[1,3-dihydroindene-2,4'-piperidine]-1'-carboxamide Chemical compound CNC(=O)C1=CC=NC(NC(=O)N2CCC3(CC4=CC(F)=CC=C4C3)CC2)=C1 PHYZSAULJWQSEQ-UHFFFAOYSA-N 0.000 claims description 2
FUHJCGFYGGUCJX-UHFFFAOYSA-N 5-fluoro-n-[4-(methylcarbamoyl)pyridin-2-yl]spiro[3h-1-benzofuran-2,4'-piperidine]-1'-carboxamide Chemical compound CNC(=O)C1=CC=NC(NC(=O)N2CCC3(OC4=CC=C(F)C=C4C3)CC2)=C1 FUHJCGFYGGUCJX-UHFFFAOYSA-N 0.000 claims description 2
HGVXTAGDJKVCDK-UHFFFAOYSA-N 6-fluoro-n-[4-(methylcarbamoyl)pyridin-2-yl]spiro[2,4-dihydro-1h-naphthalene-3,4'-piperidine]-1'-carboxamide Chemical compound CNC(=O)C1=CC=NC(NC(=O)N2CCC3(CC2)CC2=CC(F)=CC=C2CC3)=C1 HGVXTAGDJKVCDK-UHFFFAOYSA-N 0.000 claims description 2
HYDIUJYJUOWWLE-UHFFFAOYSA-N 6-fluoro-n-[4-(methylcarbamoyl)pyridin-2-yl]spiro[3h-1-benzofuran-2,4'-piperidine]-1'-carboxamide Chemical compound CNC(=O)C1=CC=NC(NC(=O)N2CCC3(OC4=CC(F)=CC=C4C3)CC2)=C1 HYDIUJYJUOWWLE-UHFFFAOYSA-N 0.000 claims description 2
YGBGLDFQYNRHAV-UHFFFAOYSA-N 6-fluoro-n-[4-[(1-methylpyrazol-4-yl)methylcarbamoyl]pyridin-2-yl]spiro[3,4-dihydrochromene-2,4'-piperidine]-1'-carboxamide Chemical compound C1=NN(C)C=C1CNC(=O)C1=CC=NC(NC(=O)N2CCC3(CC2)OC2=CC=C(F)C=C2CC3)=C1 YGBGLDFQYNRHAV-UHFFFAOYSA-N 0.000 claims description 2
OLYSEANEZKWQPH-UHFFFAOYSA-N 7-chloro-n-[4-(methylcarbamoyl)pyridin-2-yl]spiro[3h-1-benzofuran-2,4'-piperidine]-1'-carboxamide Chemical compound CNC(=O)C1=CC=NC(NC(=O)N2CCC3(OC4=C(Cl)C=CC=C4C3)CC2)=C1 OLYSEANEZKWQPH-UHFFFAOYSA-N 0.000 claims description 2
QTWOGSMPWCVSNE-UHFFFAOYSA-N 7-fluoro-n-[4-(methylcarbamoyl)pyridin-2-yl]spiro[2,4-dihydro-1h-naphthalene-3,4'-piperidine]-1'-carboxamide Chemical compound CNC(=O)C1=CC=NC(NC(=O)N2CCC3(CC2)CC2=CC=C(F)C=C2CC3)=C1 QTWOGSMPWCVSNE-UHFFFAOYSA-N 0.000 claims description 2
229940077274 Alpha glucosidase inhibitor Drugs 0.000 claims description 2
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 2
229940123208 Biguanide Drugs 0.000 claims description 2
206010006895 Cachexia Diseases 0.000 claims description 2
229920001268 Cholestyramine Polymers 0.000 claims description 2
201000004624 Dermatitis Diseases 0.000 claims description 2
208000002249 Diabetes Complications Diseases 0.000 claims description 2
201000001431 Hyperuricemia Diseases 0.000 claims description 2
102000004877 Insulin Human genes 0.000 claims description 2
108090001061 Insulin Proteins 0.000 claims description 2
229940122199 Insulin secretagogue Drugs 0.000 claims description 2
229940122355 Insulin sensitizer Drugs 0.000 claims description 2
102000016267 Leptin Human genes 0.000 claims description 2
108010092277 Leptin Proteins 0.000 claims description 2
206010033307 Overweight Diseases 0.000 claims description 2
201000004681 Psoriasis Diseases 0.000 claims description 2
102000018692 Sulfonylurea Receptors Human genes 0.000 claims description 2
108010091821 Sulfonylurea Receptors Proteins 0.000 claims description 2
206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
229960001138 acetylsalicylic acid Drugs 0.000 claims description 2
239000003888 alpha glucosidase inhibitor Substances 0.000 claims description 2
208000010668 atopic eczema Diseases 0.000 claims description 2
229940125753 fibrate Drugs 0.000 claims description 2
229940125396 insulin Drugs 0.000 claims description 2
230000002473 insulinotropic effect Effects 0.000 claims description 2
NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 claims description 2
229940039781 leptin Drugs 0.000 claims description 2
IZBOJHBDNMGYCG-UHFFFAOYSA-N n-[4-(methylcarbamoyl)pyridin-2-yl]spiro[2,4-dihydro-1h-naphthalene-3,4'-piperidine]-1'-carboxamide Chemical compound CNC(=O)C1=CC=NC(NC(=O)N2CCC3(CC2)CC2=CC=CC=C2CC3)=C1 IZBOJHBDNMGYCG-UHFFFAOYSA-N 0.000 claims description 2
XAUWTHXWHPOJJL-UHFFFAOYSA-N n-[4-(methylcarbamoyl)pyridin-2-yl]spiro[3,4-dihydrochromene-2,4'-piperidine]-1'-carboxamide Chemical compound CNC(=O)C1=CC=NC(NC(=O)N2CCC3(CC2)OC2=CC=CC=C2CC3)=C1 XAUWTHXWHPOJJL-UHFFFAOYSA-N 0.000 claims description 2
XHDXLLZIBXXFME-UHFFFAOYSA-N n-[4-(methylcarbamoyl)pyridin-2-yl]spiro[3h-1-benzofuran-2,4'-piperidine]-1'-carboxamide Chemical compound CNC(=O)C1=CC=NC(NC(=O)N2CCC3(OC4=CC=CC=C4C3)CC2)=C1 XHDXLLZIBXXFME-UHFFFAOYSA-N 0.000 claims description 2
201000004700 rosacea Diseases 0.000 claims description 2
239000004059 squalene synthase inhibitor Substances 0.000 claims description 2
208000016261 weight loss Diseases 0.000 claims description 2
230000004580 weight loss Effects 0.000 claims description 2
125000004356 hydroxy functional group Chemical group O* 0.000 claims 11
125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 1
XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 claims 1
206010012655 Diabetic complications Diseases 0.000 claims 1
102100025012 Dipeptidyl peptidase 4 Human genes 0.000 claims 1
102100025101 GATA-type zinc finger protein 1 Human genes 0.000 claims 1
101710198884 GATA-type zinc finger protein 1 Proteins 0.000 claims 1
229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
101000684208 Homo sapiens Prolyl endopeptidase FAP Proteins 0.000 claims 1
241001303601 Rosacea Species 0.000 claims 1
239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 1
239000004026 insulin derivative Substances 0.000 claims 1
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 93
102100028897 Stearoyl-CoA desaturase Human genes 0.000 description 87
238000005481 NMR spectroscopy Methods 0.000 description 67
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 60
238000002360 preparation method Methods 0.000 description 48
239000007787 solid Substances 0.000 description 45
239000000203 mixture Substances 0.000 description 42
239000000243 solution Substances 0.000 description 39
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 36
238000006243 chemical reaction Methods 0.000 description 35
238000012986 modification Methods 0.000 description 31
230000004048 modification Effects 0.000 description 31
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 30
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 28
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 28
125000002947 alkylene group Chemical group 0.000 description 28
239000011541 reaction mixture Substances 0.000 description 28
150000002632 lipids Chemical class 0.000 description 27
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 26
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 24
125000002887 hydroxy group Chemical group [H]O* 0.000 description 24
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 24
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 21
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 21
241000700605 Viruses Species 0.000 description 21
150000001732 carboxylic acid derivatives Chemical class 0.000 description 21
229940002612 prodrug Drugs 0.000 description 21
239000000651 prodrug Substances 0.000 description 21
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 20
239000012044 organic layer Substances 0.000 description 20
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 19
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 18
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 18
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 17
241001465754 Metazoa Species 0.000 description 17
239000006260 foam Substances 0.000 description 17
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 16
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 16
229920006395 saturated elastomer Polymers 0.000 description 16
150000003413 spiro compounds Chemical class 0.000 description 16
239000002253 acid Substances 0.000 description 14
230000015572 biosynthetic process Effects 0.000 description 14
238000012360 testing method Methods 0.000 description 14
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 14
AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 14
239000010410 layer Substances 0.000 description 13
238000003786 synthesis reaction Methods 0.000 description 13
0 CN(CC1)CCC1(C1)OC(C=C*(*)C=C2)=C2C1=O Chemical compound CN(CC1)CCC1(C1)OC(C=C*(*)C=C2)=C2C1=O 0.000 description 12
235000014113 dietary fatty acids Nutrition 0.000 description 12
239000000194 fatty acid Substances 0.000 description 12
229930195729 fatty acid Natural products 0.000 description 12
239000012299 nitrogen atmosphere Substances 0.000 description 12
101710159293 Acyl-CoA desaturase 1 Proteins 0.000 description 11
150000004665 fatty acids Chemical class 0.000 description 11
229910052757 nitrogen Inorganic materials 0.000 description 11
238000010992 reflux Methods 0.000 description 11
241000699670 Mus sp. Species 0.000 description 10
125000004450 alkenylene group Chemical group 0.000 description 10
238000003556 assay Methods 0.000 description 10
238000004440 column chromatography Methods 0.000 description 10
TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Chemical compound OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 description 10
125000006239 protecting group Chemical group 0.000 description 10
229940124597 therapeutic agent Drugs 0.000 description 10
BKKQXLKJWBUHTG-UHFFFAOYSA-N 7-fluorospiro[chromene-2,4'-piperidine] Chemical compound O1C2=CC(F)=CC=C2C=CC21CCNCC2 BKKQXLKJWBUHTG-UHFFFAOYSA-N 0.000 description 9
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 9
101100041816 Homo sapiens SCD gene Proteins 0.000 description 9
241000699666 Mus <mouse, genus> Species 0.000 description 9
125000004122 cyclic group Chemical group 0.000 description 9
239000002904 solvent Substances 0.000 description 9
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 8
102000004190 Enzymes Human genes 0.000 description 8
108090000790 Enzymes Proteins 0.000 description 8
230000004071 biological effect Effects 0.000 description 8
230000008859 change Effects 0.000 description 8
235000012000 cholesterol Nutrition 0.000 description 8
238000001914 filtration Methods 0.000 description 8
125000001183 hydrocarbyl group Chemical group 0.000 description 8
230000007062 hydrolysis Effects 0.000 description 8
238000006460 hydrolysis reaction Methods 0.000 description 8
238000001727 in vivo Methods 0.000 description 8
OHAGOYOEHMIMNG-UHFFFAOYSA-N methyl 2-[(4-nitrophenoxy)carbonylamino]pyridine-4-carboxylate Chemical compound COC(=O)C1=CC=NC(NC(=O)OC=2C=CC(=CC=2)[N+]([O-])=O)=C1 OHAGOYOEHMIMNG-UHFFFAOYSA-N 0.000 description 8
229910000030 sodium bicarbonate Inorganic materials 0.000 description 8
235000017557 sodium bicarbonate Nutrition 0.000 description 8
125000001424 substituent group Chemical group 0.000 description 8
210000001732 sebaceous gland Anatomy 0.000 description 7
239000007858 starting material Substances 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
208000024172 Cardiovascular disease Diseases 0.000 description 6
241000282412 Homo Species 0.000 description 6
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 6
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 6
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
108010062497 VLDL Lipoproteins Proteins 0.000 description 6
230000002159 abnormal effect Effects 0.000 description 6
238000010976 amide bond formation reaction Methods 0.000 description 6
239000002585 base Substances 0.000 description 6
150000001721 carbon Chemical group 0.000 description 6
239000003085 diluting agent Substances 0.000 description 6
229940079593 drug Drugs 0.000 description 6
238000007429 general method Methods 0.000 description 6
210000004185 liver Anatomy 0.000 description 6
239000012279 sodium borohydride Substances 0.000 description 6
229910000033 sodium borohydride Inorganic materials 0.000 description 6
125000000335 thiazolyl group Chemical group 0.000 description 6
150000003626 triacylglycerols Chemical class 0.000 description 6
NXLNNXIXOYSCMB-UHFFFAOYSA-N (4-nitrophenyl) carbonochloridate Chemical compound [O-][N+](=O)C1=CC=C(OC(Cl)=O)C=C1 NXLNNXIXOYSCMB-UHFFFAOYSA-N 0.000 description 5
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
210000004027 cell Anatomy 0.000 description 5
235000005911 diet Nutrition 0.000 description 5
230000037213 diet Effects 0.000 description 5
239000000706 filtrate Substances 0.000 description 5
125000004435 hydrogen atom Chemical group [H]* 0.000 description 5
208000006575 hypertriglyceridemia Diseases 0.000 description 5
TWBYWOBDOCUKOW-UHFFFAOYSA-M isonicotinate Chemical compound [O-]C(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-M 0.000 description 5
230000008569 process Effects 0.000 description 5
239000012453 solvate Substances 0.000 description 5
SIARJEKBADXQJG-LFZQUHGESA-N stearoyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CCCCCCCCCCCCCCCCC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 SIARJEKBADXQJG-LFZQUHGESA-N 0.000 description 5
238000003756 stirring Methods 0.000 description 5
229910052717 sulfur Inorganic materials 0.000 description 5
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
ZFDLTTNXANIPLB-UHFFFAOYSA-N 7-fluorospiro[3,4-dihydrochromene-2,4'-piperidine] Chemical compound O1C2=CC(F)=CC=C2CCC21CCNCC2 ZFDLTTNXANIPLB-UHFFFAOYSA-N 0.000 description 4
DQFSJUGTMHTBLY-UHFFFAOYSA-N 7-fluorospiro[3,4-dihydrochromene-2,4'-piperidine];hydrochloride Chemical compound Cl.O1C2=CC(F)=CC=C2CCC21CCNCC2 DQFSJUGTMHTBLY-UHFFFAOYSA-N 0.000 description 4
206010028980 Neoplasm Diseases 0.000 description 4
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
201000002150 Progressive familial intrahepatic cholestasis Diseases 0.000 description 4
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
235000019270 ammonium chloride Nutrition 0.000 description 4
230000008901 benefit Effects 0.000 description 4
125000002619 bicyclic group Chemical group 0.000 description 4
RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
239000000969 carrier Substances 0.000 description 4
239000003638 chemical reducing agent Substances 0.000 description 4
230000007812 deficiency Effects 0.000 description 4
IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 4
208000015181 infectious disease Diseases 0.000 description 4
ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 4
210000001853 liver microsome Anatomy 0.000 description 4
239000012528 membrane Substances 0.000 description 4
229940087646 methanolamine Drugs 0.000 description 4
SVWWNEYBEFASMP-UHFFFAOYSA-N methyl 2-aminopyridine-4-carboxylate Chemical compound COC(=O)C1=CC=NC(N)=C1 SVWWNEYBEFASMP-UHFFFAOYSA-N 0.000 description 4
230000003228 microsomal effect Effects 0.000 description 4
210000001589 microsome Anatomy 0.000 description 4
239000003921 oil Substances 0.000 description 4
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
150000003904 phospholipids Chemical class 0.000 description 4
239000002244 precipitate Substances 0.000 description 4
230000009467 reduction Effects 0.000 description 4
229910000104 sodium hydride Inorganic materials 0.000 description 4
239000000126 substance Substances 0.000 description 4
239000000758 substrate Substances 0.000 description 4
DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 4
DJJOZCOOKOLKGR-UHFFFAOYSA-N tert-butyl 7-fluoro-4-oxospiro[3h-chromene-2,4'-piperidine]-1'-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC21OC1=CC(F)=CC=C1C(=O)C2 DJJOZCOOKOLKGR-UHFFFAOYSA-N 0.000 description 4
OGSPWJSNOLKNSY-UHFFFAOYSA-N tert-butyl 8-chloro-4-oxospiro[3h-chromene-2,4'-piperidine]-1'-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC21OC1=C(Cl)C=CC=C1C(=O)C2 OGSPWJSNOLKNSY-UHFFFAOYSA-N 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 4
LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 3
ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 3
UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 3
FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
241000711573 Coronaviridae Species 0.000 description 3
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
201000010374 Down Syndrome Diseases 0.000 description 3
108020004206 Gamma-glutamyltransferase Proteins 0.000 description 3
101800000224 Glucagon-like peptide 1 Proteins 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
108010010234 HDL Lipoproteins Proteins 0.000 description 3
206010019708 Hepatic steatosis Diseases 0.000 description 3
241000725303 Human immunodeficiency virus Species 0.000 description 3
102000003729 Neprilysin Human genes 0.000 description 3
108090000028 Neprilysin Proteins 0.000 description 3
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 3
108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 3
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
102100040918 Pro-glucagon Human genes 0.000 description 3
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
241000700159 Rattus Species 0.000 description 3
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
235000021355 Stearic acid Nutrition 0.000 description 3
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
125000004419 alkynylene group Chemical group 0.000 description 3
125000003277 amino group Chemical group 0.000 description 3
238000010171 animal model Methods 0.000 description 3
239000003524 antilipemic agent Substances 0.000 description 3
125000004429 atom Chemical group 0.000 description 3
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
239000000872 buffer Substances 0.000 description 3
150000001720 carbohydrates Chemical class 0.000 description 3
235000014633 carbohydrates Nutrition 0.000 description 3
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
150000001840 cholesterol esters Chemical class 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
230000006806 disease prevention Effects 0.000 description 3
208000037765 diseases and disorders Diseases 0.000 description 3
238000009472 formulation Methods 0.000 description 3
239000012458 free base Substances 0.000 description 3
125000000524 functional group Chemical group 0.000 description 3
102000006640 gamma-Glutamyltransferase Human genes 0.000 description 3
208000006454 hepatitis Diseases 0.000 description 3
231100000283 hepatitis Toxicity 0.000 description 3
QNXSIUBBGPHDDE-UHFFFAOYSA-N indan-1-one Chemical compound C1=CC=C2C(=O)CCC2=C1 QNXSIUBBGPHDDE-UHFFFAOYSA-N 0.000 description 3
239000004041 inotropic agent Substances 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
239000007788 liquid Substances 0.000 description 3
239000011777 magnesium Substances 0.000 description 3
239000000463 material Substances 0.000 description 3
125000002950 monocyclic group Chemical group 0.000 description 3
125000004433 nitrogen atom Chemical group N* 0.000 description 3
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
150000007530 organic bases Chemical class 0.000 description 3
229910052760 oxygen Inorganic materials 0.000 description 3
239000001301 oxygen Substances 0.000 description 3
239000000047 product Substances 0.000 description 3
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
239000012312 sodium hydride Substances 0.000 description 3
239000008117 stearic acid Substances 0.000 description 3
231100000240 steatosis hepatitis Toxicity 0.000 description 3
238000005556 structure-activity relationship Methods 0.000 description 3
239000011593 sulfur Substances 0.000 description 3
239000000725 suspension Substances 0.000 description 3
IZHCJTGKBMXNHV-UHFFFAOYSA-N tert-butyl 6-fluoro-4-oxospiro[3h-chromene-2,4'-piperidine]-1'-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC21OC1=CC=C(F)C=C1C(=O)C2 IZHCJTGKBMXNHV-UHFFFAOYSA-N 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 2
PBHNUVVLBULHPC-UHFFFAOYSA-N (5-methyl-1,2-oxazol-3-yl)methanamine;hydrobromide Chemical compound Br.CC1=CC(CN)=NO1 PBHNUVVLBULHPC-UHFFFAOYSA-N 0.000 description 2
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
GHUULNCSFBHRCN-UHFFFAOYSA-N 1'-benzylspiro[1,3-dihydroindene-2,4'-piperidine] Chemical compound C1CC2(CC3=CC=CC=C3C2)CCN1CC1=CC=CC=C1 GHUULNCSFBHRCN-UHFFFAOYSA-N 0.000 description 2
PYOQSUKZEDSGMW-UHFFFAOYSA-N 1'-benzylspiro[1,3-dihydroindene-2,4'-piperidine]-1-ol Chemical compound OC1C2=CC=CC=C2CC1(CC1)CCN1CC1=CC=CC=C1 PYOQSUKZEDSGMW-UHFFFAOYSA-N 0.000 description 2
ROMKXPDOTZZBSQ-UHFFFAOYSA-N 1'-benzylspiro[3h-indene-2,4'-piperidine]-1-one Chemical compound O=C1C2=CC=CC=C2CC1(CC1)CCN1CC1=CC=CC=C1 ROMKXPDOTZZBSQ-UHFFFAOYSA-N 0.000 description 2
HLTBTUXAMVOKIH-UHFFFAOYSA-N 1-(4-fluoro-2-hydroxyphenyl)ethanone Chemical compound CC(=O)C1=CC=C(F)C=C1O HLTBTUXAMVOKIH-UHFFFAOYSA-N 0.000 description 2
WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
MIZIOHLLYXVEHJ-UHFFFAOYSA-N 2-[benzyl(2-hydroxyethyl)amino]ethanol Chemical compound OCCN(CCO)CC1=CC=CC=C1 MIZIOHLLYXVEHJ-UHFFFAOYSA-N 0.000 description 2
CZMRCDWAGMRECN-UHFFFAOYSA-N 2-{[3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound OCC1OC(CO)(OC2OC(CO)C(O)C(O)C2O)C(O)C1O CZMRCDWAGMRECN-UHFFFAOYSA-N 0.000 description 2
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
QCXJEYYXVJIFCE-UHFFFAOYSA-N 4-acetamidobenzoic acid Chemical compound CC(=O)NC1=CC=C(C(O)=O)C=C1 QCXJEYYXVJIFCE-UHFFFAOYSA-N 0.000 description 2
NMCKJFCJIHCHIS-UHFFFAOYSA-N 6-aminopyridine-2-carboxylic acid Chemical compound NC1=CC=CC(C(O)=O)=N1 NMCKJFCJIHCHIS-UHFFFAOYSA-N 0.000 description 2
KTMLNYJPYQAEME-UHFFFAOYSA-N 6-fluorospiro[3,4-dihydrochromene-2,4'-piperidine] Chemical compound C1CC2=CC(F)=CC=C2OC21CCNCC2 KTMLNYJPYQAEME-UHFFFAOYSA-N 0.000 description 2
UFMIWJUCWGFHTQ-UHFFFAOYSA-N 7-fluorospiro[3h-chromene-2,4'-piperidine]-4-one;hydrochloride Chemical compound Cl.O1C2=CC(F)=CC=C2C(=O)CC21CCNCC2 UFMIWJUCWGFHTQ-UHFFFAOYSA-N 0.000 description 2
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
RAAKJJLERJCLFT-UHFFFAOYSA-N 8-chlorospiro[3,4-dihydrochromene-2,4'-piperidine] Chemical compound O1C=2C(Cl)=CC=CC=2CCC21CCNCC2 RAAKJJLERJCLFT-UHFFFAOYSA-N 0.000 description 2
NTDVOZXPYKAIMP-UHFFFAOYSA-N 8-chlorospiro[3h-chromene-2,4'-piperidin-1-ium]-4-one;chloride Chemical compound Cl.O1C=2C(Cl)=CC=CC=2C(=O)CC21CCNCC2 NTDVOZXPYKAIMP-UHFFFAOYSA-N 0.000 description 2
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
241000710929 Alphavirus Species 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
102100038495 Bile acid receptor Human genes 0.000 description 2
241000283690 Bos taurus Species 0.000 description 2
239000004072 C09CA03 - Valsartan Substances 0.000 description 2
208000005145 Cerebral amyloid angiopathy Diseases 0.000 description 2
102000012336 Cholesterol Ester Transfer Proteins Human genes 0.000 description 2
108010061846 Cholesterol Ester Transfer Proteins Proteins 0.000 description 2
RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 2
RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 2
LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 2
102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 description 2
208000004930 Fatty Liver Diseases 0.000 description 2
241000710781 Flaviviridae Species 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
102000001267 GSK3 Human genes 0.000 description 2
101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 description 2
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
241000711549 Hepacivirus C Species 0.000 description 2
206010019728 Hepatitis alcoholic Diseases 0.000 description 2
101000603876 Homo sapiens Bile acid receptor Proteins 0.000 description 2
208000031226 Hyperlipidaemia Diseases 0.000 description 2
LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
108010007622 LDL Lipoproteins Proteins 0.000 description 2
102000007330 LDL Lipoproteins Human genes 0.000 description 2
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
208000021642 Muscular disease Diseases 0.000 description 2
201000009623 Myopathy Diseases 0.000 description 2
QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 2
UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 2
208000012902 Nervous system disease Diseases 0.000 description 2
208000025966 Neurological disease Diseases 0.000 description 2
108010015847 Non-Receptor Type 1 Protein Tyrosine Phosphatase Proteins 0.000 description 2
239000005642 Oleic acid Substances 0.000 description 2
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
235000021314 Palmitic acid Nutrition 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
241000709664 Picornaviridae Species 0.000 description 2
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
102000002808 Pituitary adenylate cyclase-activating polypeptide Human genes 0.000 description 2
108010004684 Pituitary adenylate cyclase-activating polypeptide Proteins 0.000 description 2
LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
241000283984 Rodentia Species 0.000 description 2
YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
241000315672 SARS coronavirus Species 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
102100033930 Stearoyl-CoA desaturase 5 Human genes 0.000 description 2
208000006011 Stroke Diseases 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
241000282898 Sus scrofa Species 0.000 description 2
241000710771 Tick-borne encephalitis virus Species 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 2
102100033001 Tyrosine-protein phosphatase non-receptor type 1 Human genes 0.000 description 2
239000004164 Wax ester Substances 0.000 description 2
WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
208000002353 alcoholic hepatitis Diseases 0.000 description 2
235000010443 alginic acid Nutrition 0.000 description 2
239000000783 alginic acid Substances 0.000 description 2
229920000615 alginic acid Polymers 0.000 description 2
229960001126 alginic acid Drugs 0.000 description 2
150000004781 alginic acids Chemical class 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
239000000883 anti-obesity agent Substances 0.000 description 2
239000003472 antidiabetic agent Substances 0.000 description 2
229940030600 antihypertensive agent Drugs 0.000 description 2
239000002220 antihypertensive agent Substances 0.000 description 2
229940125710 antiobesity agent Drugs 0.000 description 2
125000004104 aryloxy group Chemical group 0.000 description 2
230000004888 barrier function Effects 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
125000005605 benzo group Chemical group 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
239000012267 brine Substances 0.000 description 2
229960001948 caffeine Drugs 0.000 description 2
VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
159000000007 calcium salts Chemical class 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
150000003857 carboxamides Chemical class 0.000 description 2
125000003636 chemical group Chemical group 0.000 description 2
239000000460 chlorine Substances 0.000 description 2
201000001883 cholelithiasis Diseases 0.000 description 2
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
229960001231 choline Drugs 0.000 description 2
208000019425 cirrhosis of liver Diseases 0.000 description 2
RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 2
239000005516 coenzyme A Substances 0.000 description 2
229940093530 coenzyme a Drugs 0.000 description 2
208000010877 cognitive disease Diseases 0.000 description 2
239000003086 colorant Substances 0.000 description 2
238000001816 cooling Methods 0.000 description 2
238000002425 crystallisation Methods 0.000 description 2
230000008025 crystallization Effects 0.000 description 2
GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 2
238000003745 diagnosis Methods 0.000 description 2
JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 2
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 2
HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 2
229960005156 digoxin Drugs 0.000 description 2
LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 2
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
238000009826 distribution Methods 0.000 description 2
POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
239000003995 emulsifying agent Substances 0.000 description 2
RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
208000010706 fatty liver disease Diseases 0.000 description 2
239000012065 filter cake Substances 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
239000012530 fluid Substances 0.000 description 2
235000003599 food sweetener Nutrition 0.000 description 2
208000001130 gallstones Diseases 0.000 description 2
210000003494 hepatocyte Anatomy 0.000 description 2
125000005842 heteroatom Chemical group 0.000 description 2
FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
238000011534 incubation Methods 0.000 description 2
150000007529 inorganic bases Chemical class 0.000 description 2
239000000543 intermediate Substances 0.000 description 2
SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
230000037356 lipid metabolism Effects 0.000 description 2
102000004311 liver X receptors Human genes 0.000 description 2
108090000865 liver X receptors Proteins 0.000 description 2
229910052749 magnesium Inorganic materials 0.000 description 2
159000000003 magnesium salts Chemical class 0.000 description 2
238000005259 measurement Methods 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
230000002503 metabolic effect Effects 0.000 description 2
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
TVGJSKOMKREYGP-UHFFFAOYSA-N methyl 5-[(4-nitrophenoxy)carbonylamino]pyridine-3-carboxylate Chemical compound COC(=O)C1=CN=CC(NC(=O)OC=2C=CC(=CC=2)[N+]([O-])=O)=C1 TVGJSKOMKREYGP-UHFFFAOYSA-N 0.000 description 2
MBGSRKHDEJNWED-UHFFFAOYSA-N methyl 5-aminopyridine-3-carboxylate Chemical compound COC(=O)C1=CN=CC(N)=C1 MBGSRKHDEJNWED-UHFFFAOYSA-N 0.000 description 2
QZIKSCWPOQEDRO-UHFFFAOYSA-N methyl 6-[(4-nitrophenoxy)carbonylamino]pyridine-2-carboxylate Chemical compound COC(=O)C1=CC=CC(NC(=O)OC=2C=CC(=CC=2)[N+]([O-])=O)=N1 QZIKSCWPOQEDRO-UHFFFAOYSA-N 0.000 description 2
OHIHEJTUXNQOPM-UHFFFAOYSA-N methyl 6-aminopyridine-2-carboxylate Chemical compound COC(=O)C1=CC=CC(N)=N1 OHIHEJTUXNQOPM-UHFFFAOYSA-N 0.000 description 2
208000027061 mild cognitive impairment Diseases 0.000 description 2
239000002480 mineral oil Substances 0.000 description 2
235000010446 mineral oil Nutrition 0.000 description 2
235000021281 monounsaturated fatty acids Nutrition 0.000 description 2
WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
NOCFCCNGOFVBDJ-UHFFFAOYSA-N n-benzyl-2-bromo-n-(2-bromoethyl)ethanamine Chemical compound BrCCN(CCBr)CC1=CC=CC=C1 NOCFCCNGOFVBDJ-UHFFFAOYSA-N 0.000 description 2
XTEGVFVZDVNBPF-UHFFFAOYSA-N naphthalene-1,5-disulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1S(O)(=O)=O XTEGVFVZDVNBPF-UHFFFAOYSA-N 0.000 description 2
229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 2
206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 2
WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 2
125000001715 oxadiazolyl group Chemical group 0.000 description 2
CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 description 2
MNBKLUUYKPBKDU-BBECNAHFSA-N palmitoyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CCCCCCCCCCCCCCC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MNBKLUUYKPBKDU-BBECNAHFSA-N 0.000 description 2
239000006072 paste Substances 0.000 description 2
229940124531 pharmaceutical excipient Drugs 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 description 2
HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
201000010065 polycystic ovary syndrome Diseases 0.000 description 2
235000020777 polyunsaturated fatty acids Nutrition 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
239000002243 precursor Substances 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 2
229960003401 ramipril Drugs 0.000 description 2
230000000241 respiratory effect Effects 0.000 description 2
208000023504 respiratory system disease Diseases 0.000 description 2
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 2
RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 2
201000002859 sleep apnea Diseases 0.000 description 2
159000000000 sodium salts Chemical class 0.000 description 2
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
AJOICBZPOILCTP-UHFFFAOYSA-N spiro[1,3-dihydroindene-2,4'-piperidine] Chemical compound C1C2=CC=CC=C2CC11CCNCC1 AJOICBZPOILCTP-UHFFFAOYSA-N 0.000 description 2
238000012453 sprague-dawley rat model Methods 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical compound [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 2
125000004434 sulfur atom Chemical group 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
239000003765 sweetening agent Substances 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 description 2
UMWJMMPXYRRPJC-UHFFFAOYSA-N tert-butyl 8-chloro-4-hydroxyspiro[3,4-dihydrochromene-2,4'-piperidine]-1'-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC21OC1=C(Cl)C=CC=C1C(O)C2 UMWJMMPXYRRPJC-UHFFFAOYSA-N 0.000 description 2
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
125000001412 tetrahydropyranyl group Chemical group 0.000 description 2
YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
ZMZDMBWJUHKJPS-UHFFFAOYSA-N thiocyanic acid Chemical compound SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 2
125000003396 thiol group Chemical group [H]S* 0.000 description 2
125000004568 thiomorpholinyl group Chemical group 0.000 description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
229960004699 valsartan Drugs 0.000 description 2
SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 description 2
230000003612 virological effect Effects 0.000 description 2
235000019386 wax ester Nutrition 0.000 description 2
239000000080 wetting agent Substances 0.000 description 2
IPJABYVHNXMKEV-UHFFFAOYSA-N (1-methylpyrazol-4-yl)methanamine;hydrochloride Chemical compound Cl.CN1C=C(CN)C=N1 IPJABYVHNXMKEV-UHFFFAOYSA-N 0.000 description 1
QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
BOOOLEGQBVUTKC-NVQSDHBMSA-N (2e,4e)-3-methyl-5-[(1s,2s)-2-methyl-2-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)cyclopropyl]penta-2,4-dienoic acid Chemical compound OC(=O)\C=C(/C)\C=C\[C@@H]1C[C@]1(C)C1=CC=C2C(C)(C)CCC(C)(C)C2=C1 BOOOLEGQBVUTKC-NVQSDHBMSA-N 0.000 description 1
FONCZICQWCUXEB-RUZDIDTESA-N (2r)-2-[4-(9-bromo-2,3-dimethylbenzo[f][1]benzothiol-4-yl)-2,6-dimethylphenoxy]-3-phenylpropanoic acid Chemical compound C([C@@H](OC1=C(C)C=C(C=C1C)C=1C2=CC=CC=C2C(Br)=C2SC(=C(C2=1)C)C)C(O)=O)C1=CC=CC=C1 FONCZICQWCUXEB-RUZDIDTESA-N 0.000 description 1
LPUDGHQMOAHMMF-JBACZVJFSA-N (2s)-2-[[[(2s)-6-amino-2-(methanesulfonamido)hexanoyl]amino]methyl]-3-[1-[[(1s)-1-carboxy-2-(4-hydroxyphenyl)ethyl]carbamoyl]cyclopentyl]propanoic acid Chemical compound N([C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C(=O)C1(C[C@@H](CNC(=O)[C@H](CCCCN)NS(=O)(=O)C)C(O)=O)CCCC1 LPUDGHQMOAHMMF-JBACZVJFSA-N 0.000 description 1
BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 description 1
ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 1
ZGGHKIMDNBDHJB-RPQBTBOMSA-M (3S,5R)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@H](O)C[C@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-RPQBTBOMSA-M 0.000 description 1
VDSBXXDKCUBMQC-HNGSOEQISA-N (4r,6s)-6-[(e)-2-[2-(4-fluoro-3-methylphenyl)-4,4,6,6-tetramethylcyclohexen-1-yl]ethenyl]-4-hydroxyoxan-2-one Chemical compound C1=C(F)C(C)=CC(C=2CC(C)(C)CC(C)(C)C=2\C=C\[C@H]2OC(=O)C[C@H](O)C2)=C1 VDSBXXDKCUBMQC-HNGSOEQISA-N 0.000 description 1
MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 1
WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
NLWPPAMVAMALDF-UHFFFAOYSA-N 1'-tert-butyl-7-fluorospiro[3,4-dihydrochromene-2,4'-piperidine]-4-ol Chemical compound CC(C)(C)N1CCC2(CC1)CC(O)c1ccc(F)cc1O2 NLWPPAMVAMALDF-UHFFFAOYSA-N 0.000 description 1
125000005988 1,1-dioxo-thiomorpholinyl group Chemical group 0.000 description 1
YZVFSQQHQPPKNX-UHFFFAOYSA-N 1,3-thiazole-5-carboxylic acid Chemical compound OC(=O)C1=CN=CS1 YZVFSQQHQPPKNX-UHFFFAOYSA-N 0.000 description 1
GBWVDQBTXFIIJF-UHFFFAOYSA-N 1-(3-chloro-2-hydroxyphenyl)ethanone Chemical compound CC(=O)C1=CC=CC(Cl)=C1O GBWVDQBTXFIIJF-UHFFFAOYSA-N 0.000 description 1
KOFFXZYMDLWRHX-UHFFFAOYSA-N 1-(5-fluoro-2-hydroxyphenyl)ethanone Chemical compound CC(=O)C1=CC(F)=CC=C1O KOFFXZYMDLWRHX-UHFFFAOYSA-N 0.000 description 1
VXNZUUAINFGPBY-UHFFFAOYSA-N 1-Butene Chemical group CCC=C VXNZUUAINFGPBY-UHFFFAOYSA-N 0.000 description 1
125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
JFLSOKIMYBSASW-UHFFFAOYSA-N 1-chloro-2-[chloro(diphenyl)methyl]benzene Chemical compound ClC1=CC=CC=C1C(Cl)(C=1C=CC=CC=1)C1=CC=CC=C1 JFLSOKIMYBSASW-UHFFFAOYSA-N 0.000 description 1
SJJCQDRGABAVBB-UHFFFAOYSA-N 1-hydroxy-2-naphthoic acid Chemical compound C1=CC=CC2=C(O)C(C(=O)O)=CC=C21 SJJCQDRGABAVBB-UHFFFAOYSA-N 0.000 description 1
RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
125000005987 1-oxo-thiomorpholinyl group Chemical group 0.000 description 1
FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 description 1
ABEXEQSGABRUHS-UHFFFAOYSA-N 16-methylheptadecyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC(C)C ABEXEQSGABRUHS-UHFFFAOYSA-N 0.000 description 1
125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
WOXFMYVTSLAQMO-UHFFFAOYSA-N 2-Pyridinemethanamine Chemical compound NCC1=CC=CC=N1 WOXFMYVTSLAQMO-UHFFFAOYSA-N 0.000 description 1
NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
229940013085 2-diethylaminoethanol Drugs 0.000 description 1
KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 1
125000004638 2-oxopiperazinyl group Chemical group O=C1N(CCNC1)* 0.000 description 1
125000004637 2-oxopiperidinyl group Chemical group O=C1N(CCCC1)* 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 description 1
UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
JHNLZOVBAQWGQU-UHFFFAOYSA-N 380814_sial Chemical compound CS(O)(=O)=O.O=P(=O)OP(=O)=O JHNLZOVBAQWGQU-UHFFFAOYSA-N 0.000 description 1
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 description 1
WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
125000005986 4-piperidonyl group Chemical group 0.000 description 1
BYIORJAACCWFPU-UHFFFAOYSA-N 5-aminonicotinic acid Chemical compound NC1=CN=CC(C(O)=O)=C1 BYIORJAACCWFPU-UHFFFAOYSA-N 0.000 description 1
RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 description 1
ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
GPBZOCPJOHYMJZ-UHFFFAOYSA-N 6-fluoro-n-[4-[(1-methylpyrazol-4-yl)methylcarbamoyl]pyridin-2-yl]spiro[3,4-dihydrochromene-2,4'-piperidine]-1'-carboxamide;hydrochloride Chemical compound Cl.C1=NN(C)C=C1CNC(=O)C1=CC=NC(NC(=O)N2CCC3(CC2)OC2=CC=C(F)C=C2CC3)=C1 GPBZOCPJOHYMJZ-UHFFFAOYSA-N 0.000 description 1
JWNQUBOFNBXCTI-UHFFFAOYSA-N 6-fluoro-n-[4-[(5-methyl-1,2-oxazol-3-yl)methylcarbamoyl]pyridin-2-yl]spiro[3,4-dihydrochromene-2,4'-piperidine]-1'-carboxamide;hydrochloride Chemical compound Cl.O1C(C)=CC(CNC(=O)C=2C=C(NC(=O)N3CCC4(CC3)OC3=CC=C(F)C=C3CC4)N=CC=2)=N1 JWNQUBOFNBXCTI-UHFFFAOYSA-N 0.000 description 1
QWBGQODPRFPBGQ-UHFFFAOYSA-N 7-fluoro-n-[4-(methylcarbamoyl)pyridin-2-yl]-4-oxospiro[3h-chromene-2,4'-piperidine]-1'-carboxamide;hydrochloride Chemical compound Cl.CNC(=O)C1=CC=NC(NC(=O)N2CCC3(CC2)OC2=CC(F)=CC=C2C(=O)C3)=C1 QWBGQODPRFPBGQ-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
SNJKFRIVNCWDKY-UHFFFAOYSA-N 8-chloro-n-[4-(methylcarbamoyl)pyridin-2-yl]-4-oxospiro[3h-chromene-2,4'-piperidine]-1'-carboxamide;hydrochloride Chemical compound Cl.CNC(=O)C1=CC=NC(NC(=O)N2CCC3(CC2)OC2=C(Cl)C=CC=C2C(=O)C3)=C1 SNJKFRIVNCWDKY-UHFFFAOYSA-N 0.000 description 1
NEXPMMGQJLLGLW-UHFFFAOYSA-N 8-chloro-n-[4-(methylcarbamoyl)pyridin-2-yl]spiro[3,4-dihydrochromene-2,4'-piperidine]-1'-carboxamide;hydrochloride Chemical compound Cl.CNC(=O)C1=CC=NC(NC(=O)N2CCC3(CC2)OC2=C(Cl)C=CC=C2CC3)=C1 NEXPMMGQJLLGLW-UHFFFAOYSA-N 0.000 description 1
FYOLIEIOJJYUQU-UHFFFAOYSA-N 8-chlorospiro[3h-chromene-2,4'-piperidine]-4-one Chemical compound O1C=2C(Cl)=CC=CC=2C(=O)CC21CCNCC2 FYOLIEIOJJYUQU-UHFFFAOYSA-N 0.000 description 1
108091006112 ATPases Proteins 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
102100034542 Acyl-CoA (8-3)-desaturase Human genes 0.000 description 1
102100034544 Acyl-CoA 6-desaturase Human genes 0.000 description 1
102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
208000023434 Alpers-Huttenlocher syndrome Diseases 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
229940123413 Angiotensin II antagonist Drugs 0.000 description 1
108010071619 Apolipoproteins Proteins 0.000 description 1
102000007592 Apolipoproteins Human genes 0.000 description 1
102000013918 Apolipoproteins E Human genes 0.000 description 1
108010025628 Apolipoproteins E Proteins 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
206010003210 Arteriosclerosis Diseases 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
206010003694 Atrophy Diseases 0.000 description 1
241000271566 Aves Species 0.000 description 1
125000006847 BOC protecting group Chemical group 0.000 description 1
XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
206010004637 Bile duct stone Diseases 0.000 description 1
208000020925 Bipolar disease Diseases 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
241001503592 Bovine calicivirus Species 0.000 description 1
241000711443 Bovine coronavirus Species 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
208000032841 Bulimia Diseases 0.000 description 1
206010006550 Bulimia nervosa Diseases 0.000 description 1
239000002083 C09CA01 - Losartan Substances 0.000 description 1
239000002080 C09CA02 - Eprosartan Substances 0.000 description 1
239000002947 C09CA04 - Irbesartan Substances 0.000 description 1
239000002053 C09CA06 - Candesartan Substances 0.000 description 1
239000005537 C09CA07 - Telmisartan Substances 0.000 description 1
GUSGRLNQGFGAOJ-UHFFFAOYSA-N COC(c1cccc(NC(N(CC2)CCC22Oc3cc(F)ccc3CC2)=O)n1)=O Chemical compound COC(c1cccc(NC(N(CC2)CCC22Oc3cc(F)ccc3CC2)=O)n1)=O GUSGRLNQGFGAOJ-UHFFFAOYSA-N 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
229940127291 Calcium channel antagonist Drugs 0.000 description 1
LSPHULWDVZXLIL-UHFFFAOYSA-N Camphoric acid Natural products CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
241000711506 Canine coronavirus Species 0.000 description 1
239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
208000005623 Carcinogenesis Diseases 0.000 description 1
102000002666 Carnitine O-palmitoyltransferase Human genes 0.000 description 1
108010018424 Carnitine O-palmitoyltransferase Proteins 0.000 description 1
102100027943 Carnitine O-palmitoyltransferase 1, liver isoform Human genes 0.000 description 1
101710120614 Carnitine O-palmitoyltransferase 1, liver isoform Proteins 0.000 description 1
101710108984 Carnitine O-palmitoyltransferase 1, muscle isoform Proteins 0.000 description 1
201000002929 Carnitine palmitoyltransferase II deficiency Diseases 0.000 description 1
206010050215 Carnitine palmitoyltransferase deficiency Diseases 0.000 description 1
206010008027 Cerebellar atrophy Diseases 0.000 description 1
208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 description 1
241001502567 Chikungunya virus Species 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
206010008635 Cholestasis Diseases 0.000 description 1
208000017164 Chronobiology disease Diseases 0.000 description 1
WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
241000710777 Classical swine fever virus Species 0.000 description 1
206010010904 Convulsion Diseases 0.000 description 1
241000709687 Coxsackievirus Species 0.000 description 1
241000699800 Cricetinae Species 0.000 description 1
201000003883 Cystic fibrosis Diseases 0.000 description 1
102100031655 Cytochrome b5 Human genes 0.000 description 1
102100033149 Cytochrome b5 reductase 4 Human genes 0.000 description 1
108030005700 Cytochrome-b5 reductases Proteins 0.000 description 1
108010007167 Cytochromes b5 Proteins 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
108010073542 Delta-5 Fatty Acid Desaturase Proteins 0.000 description 1
206010067889 Dementia with Lewy bodies Diseases 0.000 description 1
208000001490 Dengue Diseases 0.000 description 1
206010012310 Dengue fever Diseases 0.000 description 1
YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
206010012742 Diarrhoea infectious Diseases 0.000 description 1
208000004986 Diffuse Cerebral Sclerosis of Schilder Diseases 0.000 description 1
JRWZLRBJNMZMFE-UHFFFAOYSA-N Dobutamine Chemical compound C=1C=C(O)C(O)=CC=1CCNC(C)CCC1=CC=C(O)C=C1 JRWZLRBJNMZMFE-UHFFFAOYSA-N 0.000 description 1
206010072268 Drug-induced liver injury Diseases 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
241000710945 Eastern equine encephalitis virus Species 0.000 description 1
108010061435 Enalapril Proteins 0.000 description 1
206010014596 Encephalitis Japanese B Diseases 0.000 description 1
241000710188 Encephalomyocarditis virus Species 0.000 description 1
241000709661 Enterovirus Species 0.000 description 1
206010066919 Epidemic polyarthritis Diseases 0.000 description 1
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
108010011459 Exenatide Proteins 0.000 description 1
206010015719 Exsanguination Diseases 0.000 description 1
102000036181 Fatty Acid Elongases Human genes 0.000 description 1
108010058732 Fatty Acid Elongases Proteins 0.000 description 1
102000009114 Fatty acid desaturases Human genes 0.000 description 1
241000711475 Feline infectious peritonitis virus Species 0.000 description 1
YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
208000024412 Friedreich ataxia Diseases 0.000 description 1
241000531123 GB virus C Species 0.000 description 1
DSLZVSRJTYRBFB-UHFFFAOYSA-N Galactaric acid Natural products OC(=O)C(O)C(O)C(O)C(O)C(O)=O DSLZVSRJTYRBFB-UHFFFAOYSA-N 0.000 description 1
IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
208000005577 Gastroenteritis Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 description 1
208000002705 Glucose Intolerance Diseases 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
108010046163 Glycogen Phosphorylase Proteins 0.000 description 1
102000007390 Glycogen Phosphorylase Human genes 0.000 description 1
238000003747 Grignard reaction Methods 0.000 description 1
108010023302 HDL Cholesterol Proteins 0.000 description 1
208000036066 Hemophagocytic Lymphohistiocytosis Diseases 0.000 description 1
241000700721 Hepatitis B virus Species 0.000 description 1
241000709721 Hepatovirus A Species 0.000 description 1
208000033981 Hereditary haemochromatosis Diseases 0.000 description 1
206010063491 Herpes zoster oticus Diseases 0.000 description 1
101100309604 Homo sapiens SCD5 gene Proteins 0.000 description 1
101000639987 Homo sapiens Stearoyl-CoA desaturase 5 Proteins 0.000 description 1
244000309467 Human Coronavirus Species 0.000 description 1
241001479210 Human astrovirus Species 0.000 description 1
241001428935 Human coronavirus OC43 Species 0.000 description 1
208000035150 Hypercholesterolemia Diseases 0.000 description 1
208000001021 Hyperlipoproteinemia Type I Diseases 0.000 description 1
208000028482 Hypothalamic disease Diseases 0.000 description 1
208000025282 Hypothalamo-pituitary disease Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
241000711450 Infectious bronchitis virus Species 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
206010065973 Iron Overload Diseases 0.000 description 1
102000008133 Iron-Binding Proteins Human genes 0.000 description 1
108010035210 Iron-Binding Proteins Proteins 0.000 description 1
208000032382 Ischaemic stroke Diseases 0.000 description 1
241000764238 Isis Species 0.000 description 1
201000005807 Japanese encephalitis Diseases 0.000 description 1
PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
108010028554 LDL Cholesterol Proteins 0.000 description 1
238000008214 LDL Cholesterol Methods 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
241000710770 Langat virus Species 0.000 description 1
239000005639 Lauric acid Substances 0.000 description 1
201000002832 Lewy body dementia Diseases 0.000 description 1
102000003960 Ligases Human genes 0.000 description 1
108090000364 Ligases Proteins 0.000 description 1
108010037138 Linoleoyl-CoA Desaturase Proteins 0.000 description 1
108010007859 Lisinopril Proteins 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
241000608292 Mayaro virus Species 0.000 description 1
241000710185 Mengo virus Species 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
UWWDHYUMIORJTA-HSQYWUDLSA-N Moexipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC(OC)=C(OC)C=C2C1)C(O)=O)CC1=CC=CC=C1 UWWDHYUMIORJTA-HSQYWUDLSA-N 0.000 description 1
PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
241000711466 Murine hepatitis virus Species 0.000 description 1
241000710908 Murray Valley encephalitis virus Species 0.000 description 1
241000699660 Mus musculus Species 0.000 description 1
101100309601 Mus musculus Scd3 gene Proteins 0.000 description 1
102100026784 Myelin proteolipid protein Human genes 0.000 description 1
KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
PHSPJQZRQAJPPF-UHFFFAOYSA-N N-alpha-Methylhistamine Chemical compound CNCCC1=CN=CN1 PHSPJQZRQAJPPF-UHFFFAOYSA-N 0.000 description 1
HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
241000714209 Norwalk virus Species 0.000 description 1
229910003849 O-Si Inorganic materials 0.000 description 1
WXNNNUVVMWDBOJ-UHFFFAOYSA-N OC(c1ccnc(NC(N(CC2)CCC2(CC(c2ccc3)=O)Oc2c3Cl)=O)c1)=O Chemical compound OC(c1ccnc(NC(N(CC2)CCC2(CC(c2ccc3)=O)Oc2c3Cl)=O)c1)=O WXNNNUVVMWDBOJ-UHFFFAOYSA-N 0.000 description 1
208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
241000725177 Omsk hemorrhagic fever virus Species 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
208000001132 Osteoporosis Diseases 0.000 description 1
102000004316 Oxidoreductases Human genes 0.000 description 1
108090000854 Oxidoreductases Proteins 0.000 description 1
229910003872 O—Si Inorganic materials 0.000 description 1
108010016731 PPAR gamma Proteins 0.000 description 1
235000021319 Palmitoleic acid Nutrition 0.000 description 1
206010033645 Pancreatitis Diseases 0.000 description 1
208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
208000031481 Pathologic Constriction Diseases 0.000 description 1
208000017493 Pelizaeus-Merzbacher disease Diseases 0.000 description 1
208000018262 Peripheral vascular disease Diseases 0.000 description 1
102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 1
241000710778 Pestivirus Species 0.000 description 1
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
208000000474 Poliomyelitis Diseases 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
241000156302 Porcine hemagglutinating encephalomyelitis virus Species 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
241001533393 Potyviridae Species 0.000 description 1
241000710078 Potyvirus Species 0.000 description 1
TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
206010036618 Premenstrual syndrome Diseases 0.000 description 1
ODHCTXKNWHHXJC-GSVOUGTGSA-N Pyroglutamic acid Natural products OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 description 1
IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
241000903330 Rabbit coronavirus Species 0.000 description 1
241001428933 Rat coronavirus Species 0.000 description 1
208000017442 Retinal disease Diseases 0.000 description 1
206010038923 Retinopathy Diseases 0.000 description 1
208000006289 Rett Syndrome Diseases 0.000 description 1
241000538730 Rocio Species 0.000 description 1
241000710942 Ross River virus Species 0.000 description 1
241000710799 Rubella virus Species 0.000 description 1
SIARJEKBADXQJG-UDVGOQGCSA-N S-[2-[3-[[(2R)-4-[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-2-hydroxy-3,3-dimethylbutanoyl]amino]propanoylamino]ethyl] 9,10-ditritiooctadecanethioate Chemical compound C(CCCCCCCC(C(CCCCCCCC)[3H])[3H])(=O)SCCNC(CCNC([C@@H](C(COP(OP(OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=NC=2C(N)=NC=NC1=2)O)OP(=O)(O)O)(=O)O)(=O)O)(C)C)O)=O)=O SIARJEKBADXQJG-UDVGOQGCSA-N 0.000 description 1
101150097713 SCD1 gene Proteins 0.000 description 1
RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 description 1
101100101423 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) UBI4 gene Proteins 0.000 description 1
101150042597 Scd2 gene Proteins 0.000 description 1
241000710961 Semliki Forest virus Species 0.000 description 1
241000008910 Severe acute respiratory syndrome-related coronavirus Species 0.000 description 1
241000710960 Sindbis virus Species 0.000 description 1
208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
102100037202 Sodium/myo-inositol cotransporter 2 Human genes 0.000 description 1
101710090560 Sodium/myo-inositol cotransporter 2 Proteins 0.000 description 1
241000710888 St. Louis encephalitis virus Species 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
229940100389 Sulfonylurea Drugs 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
239000004809 Teflon Substances 0.000 description 1
229920006362 Teflon® Polymers 0.000 description 1
229940123464 Thiazolidinedione Drugs 0.000 description 1
208000004006 Tick-borne encephalitis Diseases 0.000 description 1
241000710924 Togaviridae Species 0.000 description 1
NGBFQHCMQULJNZ-UHFFFAOYSA-N Torsemide Chemical compound CC(C)NC(=O)NS(=O)(=O)C1=CN=CC=C1NC1=CC=CC(C)=C1 NGBFQHCMQULJNZ-UHFFFAOYSA-N 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
102000004357 Transferases Human genes 0.000 description 1
108090000992 Transferases Proteins 0.000 description 1
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
241000711508 Turkey coronavirus Species 0.000 description 1
241000710959 Venezuelan equine encephalitis virus Species 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
239000003875 Wang resin Substances 0.000 description 1
241000710886 West Nile virus Species 0.000 description 1
241000710951 Western equine encephalitis virus Species 0.000 description 1
241000710772 Yellow fever virus Species 0.000 description 1
241000120645 Yellow fever virus group Species 0.000 description 1
NERFNHBZJXXFGY-UHFFFAOYSA-N [4-[(4-methylphenyl)methoxy]phenyl]methanol Chemical compound C1=CC(C)=CC=C1COC1=CC=C(CO)C=C1 NERFNHBZJXXFGY-UHFFFAOYSA-N 0.000 description 1
YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
230000003187 abdominal effect Effects 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
239000002250 absorbent Substances 0.000 description 1
230000002745 absorbent Effects 0.000 description 1
229960002632 acarbose Drugs 0.000 description 1
XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
GOEMGAFJFRBGGG-UHFFFAOYSA-N acebutolol Chemical compound CCCC(=O)NC1=CC=C(OCC(O)CNC(C)C)C(C(C)=O)=C1 GOEMGAFJFRBGGG-UHFFFAOYSA-N 0.000 description 1
229960002122 acebutolol Drugs 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
229960004308 acetylcysteine Drugs 0.000 description 1
ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
239000013543 active substance Substances 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
230000003044 adaptive effect Effects 0.000 description 1
239000001361 adipic acid Substances 0.000 description 1
235000011037 adipic acid Nutrition 0.000 description 1
229960000250 adipic acid Drugs 0.000 description 1
210000001789 adipocyte Anatomy 0.000 description 1
239000008272 agar Substances 0.000 description 1
235000010419 agar Nutrition 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
125000005119 alkyl cycloalkyl group Chemical group 0.000 description 1
AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
235000001014 amino acid Nutrition 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
229960004909 aminosalicylic acid Drugs 0.000 description 1
HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 1
229960000528 amlodipine Drugs 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
238000004873 anchoring Methods 0.000 description 1
239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
230000003178 anti-diabetic effect Effects 0.000 description 1
229940125708 antidiabetic agent Drugs 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
229960003121 arginine Drugs 0.000 description 1
208000011775 arteriosclerosis disease Diseases 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
229960005261 aspartic acid Drugs 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
244000309743 astrovirus Species 0.000 description 1
229960005370 atorvastatin Drugs 0.000 description 1
230000037444 atrophy Effects 0.000 description 1
229960004530 benazepril Drugs 0.000 description 1
JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
NHVHYFAWHCJELN-UHFFFAOYSA-N benzene;n,n-dimethylformamide Chemical compound CN(C)C=O.C1=CC=CC=C1 NHVHYFAWHCJELN-UHFFFAOYSA-N 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
229940092714 benzenesulfonic acid Drugs 0.000 description 1
125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
125000005870 benzindolyl group Chemical group 0.000 description 1
125000000928 benzodioxinyl group Chemical group O1C(=COC2=C1C=CC=C2)* 0.000 description 1
125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
229960004365 benzoic acid Drugs 0.000 description 1
150000001558 benzoic acid derivatives Chemical class 0.000 description 1
125000005878 benzonaphthofuranyl group Chemical group 0.000 description 1
125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 1
125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
UIEATEWHFDRYRU-UHFFFAOYSA-N bepridil Chemical compound C1CCCN1C(COCC(C)C)CN(C=1C=CC=CC=1)CC1=CC=CC=C1 UIEATEWHFDRYRU-UHFFFAOYSA-N 0.000 description 1
229960003665 bepridil Drugs 0.000 description 1
102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
229960003237 betaine Drugs 0.000 description 1
229960004324 betaxolol Drugs 0.000 description 1
NWIUTZDMDHAVTP-UHFFFAOYSA-N betaxolol Chemical compound C1=CC(OCC(O)CNC(C)C)=CC=C1CCOCC1CC1 NWIUTZDMDHAVTP-UHFFFAOYSA-N 0.000 description 1
150000004283 biguanides Chemical class 0.000 description 1
210000000941 bile Anatomy 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
VHYCDWMUTMEGQY-UHFFFAOYSA-N bisoprolol Chemical compound CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 VHYCDWMUTMEGQY-UHFFFAOYSA-N 0.000 description 1
229960002781 bisoprolol Drugs 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
230000037396 body weight Effects 0.000 description 1
229910000085 borane Inorganic materials 0.000 description 1
UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
125000001246 bromo group Chemical group Br* 0.000 description 1
206010006451 bronchitis Diseases 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000000480 calcium channel blocker Substances 0.000 description 1
LSPHULWDVZXLIL-QUBYGPBYSA-N camphoric acid Chemical compound CC1(C)[C@H](C(O)=O)CC[C@]1(C)C(O)=O LSPHULWDVZXLIL-QUBYGPBYSA-N 0.000 description 1
230000036952 cancer formation Effects 0.000 description 1
208000035269 cancer or benign tumor Diseases 0.000 description 1
229960000932 candesartan Drugs 0.000 description 1
SGZAIDDFHDDFJU-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SGZAIDDFHDDFJU-UHFFFAOYSA-N 0.000 description 1
KHAVLLBUVKBTBG-UHFFFAOYSA-N caproleic acid Natural products OC(=O)CCCCCCCC=C KHAVLLBUVKBTBG-UHFFFAOYSA-N 0.000 description 1
239000002775 capsule Substances 0.000 description 1
229960000830 captopril Drugs 0.000 description 1
FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
231100000504 carcinogenesis Toxicity 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
208000026106 cerebrovascular disease Diseases 0.000 description 1
229960005110 cerivastatin Drugs 0.000 description 1
SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 description 1
GPUADMRJQVPIAS-QCVDVZFFSA-M cerivastatin sodium Chemical compound [Na+].COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 GPUADMRJQVPIAS-QCVDVZFFSA-M 0.000 description 1
239000003610 charcoal Substances 0.000 description 1
JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
239000012069 chiral reagent Substances 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
230000007870 cholestasis Effects 0.000 description 1
231100000359 cholestasis Toxicity 0.000 description 1
230000001587 cholestatic effect Effects 0.000 description 1
VZWXIQHBIQLMPN-UHFFFAOYSA-N chromane Chemical compound C1=CC=C2CCCOC2=C1 VZWXIQHBIQLMPN-UHFFFAOYSA-N 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
235000013985 cinnamic acid Nutrition 0.000 description 1
229930016911 cinnamic acid Natural products 0.000 description 1
125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 description 1
238000000576 coating method Methods 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
230000006957 competitive inhibition Effects 0.000 description 1
238000011109 contamination Methods 0.000 description 1
150000001879 copper Chemical class 0.000 description 1
208000029078 coronary artery disease Diseases 0.000 description 1
239000006071 cream Substances 0.000 description 1
239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
125000006448 cycloalkyl cycloalkyl group Chemical group 0.000 description 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
229950003040 dalvastatin Drugs 0.000 description 1
229960002887 deanol Drugs 0.000 description 1
125000005507 decahydroisoquinolyl group Chemical group 0.000 description 1
125000004855 decalinyl group Chemical group C1(CCCC2CCCCC12)* 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
208000025729 dengue disease Diseases 0.000 description 1
230000008021 deposition Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
229910052805 deuterium Inorganic materials 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
150000004683 dihydrates Chemical class 0.000 description 1
HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
229960004166 diltiazem Drugs 0.000 description 1
125000005879 dioxolanyl group Chemical group 0.000 description 1
125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
229960001089 dobutamine Drugs 0.000 description 1
MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
238000009510 drug design Methods 0.000 description 1
201000008865 drug-induced hepatitis Diseases 0.000 description 1
241001493065 dsRNA viruses Species 0.000 description 1
239000000975 dye Substances 0.000 description 1
208000001848 dysentery Diseases 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
229960000873 enalapril Drugs 0.000 description 1
206010014599 encephalitis Diseases 0.000 description 1
238000007824 enzymatic assay Methods 0.000 description 1
OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 description 1
229960004563 eprosartan Drugs 0.000 description 1
201000008220 erythropoietic protoporphyria Diseases 0.000 description 1
AVOLMBLBETYQHX-UHFFFAOYSA-N etacrynic acid Chemical compound CCC(=C)C(=O)C1=CC=C(OCC(O)=O)C(Cl)=C1Cl AVOLMBLBETYQHX-UHFFFAOYSA-N 0.000 description 1
229960003199 etacrynic acid Drugs 0.000 description 1
AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 description 1
VFRSADQPWYCXDG-LEUCUCNGSA-N ethyl (2s,5s)-5-methylpyrrolidine-2-carboxylate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCOC(=O)[C@@H]1CC[C@H](C)N1 VFRSADQPWYCXDG-LEUCUCNGSA-N 0.000 description 1
WZHUPCREDVWLKC-UHFFFAOYSA-N ethyl 2-amino-4-methyl-1,3-thiazole-5-carboxylate Chemical compound CCOC(=O)C=1SC(N)=NC=1C WZHUPCREDVWLKC-UHFFFAOYSA-N 0.000 description 1
GWNFQAKCJYEJEW-UHFFFAOYSA-N ethyl 3-[8-[[4-methyl-5-[(3-methyl-4-oxophthalazin-1-yl)methyl]-1,2,4-triazol-3-yl]sulfanyl]octanoylamino]benzoate Chemical compound CCOC(=O)C1=CC(NC(=O)CCCCCCCSC2=NN=C(CC3=NN(C)C(=O)C4=CC=CC=C34)N2C)=CC=C1 GWNFQAKCJYEJEW-UHFFFAOYSA-N 0.000 description 1
XRLFVWGWTMEYFX-UHFFFAOYSA-N ethyl 4-methyl-2-[(4-nitrophenoxy)carbonylamino]-1,3-thiazole-5-carboxylate Chemical compound CC1=C(C(=O)OCC)SC(NC(=O)OC=2C=CC(=CC=2)[N+]([O-])=O)=N1 XRLFVWGWTMEYFX-UHFFFAOYSA-N 0.000 description 1
PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 1
229960001519 exenatide Drugs 0.000 description 1
208000030533 eye disease Diseases 0.000 description 1
210000000744 eyelid Anatomy 0.000 description 1
208000029944 familial hemophagocytic lymphohistiocytosis type 1 Diseases 0.000 description 1
230000004129 fatty acid metabolism Effects 0.000 description 1
229960003580 felodipine Drugs 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
229960003765 fluvastatin Drugs 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
230000037406 food intake Effects 0.000 description 1
235000012631 food intake Nutrition 0.000 description 1
235000019253 formic acid Nutrition 0.000 description 1
229960002490 fosinopril Drugs 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
229960003883 furosemide Drugs 0.000 description 1
125000002541 furyl group Chemical group 0.000 description 1
DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 description 1
210000000232 gallbladder Anatomy 0.000 description 1
229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
201000011349 geniculate herpes zoster Diseases 0.000 description 1
229960005219 gentisic acid Drugs 0.000 description 1
239000011521 glass Substances 0.000 description 1
229960004580 glibenclamide Drugs 0.000 description 1
ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 1
229960001381 glipizide Drugs 0.000 description 1
239000000174 gluconic acid Substances 0.000 description 1
235000012208 gluconic acid Nutrition 0.000 description 1
229960002442 glucosamine Drugs 0.000 description 1
229940097043 glucuronic acid Drugs 0.000 description 1
ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 1
229940093915 gynecological organic acid Drugs 0.000 description 1
BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
229960003132 halothane Drugs 0.000 description 1
208000019622 heart disease Diseases 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
201000010284 hepatitis E Diseases 0.000 description 1
231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
206010073071 hepatocellular carcinoma Diseases 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
229960002885 histidine Drugs 0.000 description 1
238000000265 homogenisation Methods 0.000 description 1
XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
238000005984 hydrogenation reaction Methods 0.000 description 1
150000002440 hydroxy compounds Chemical class 0.000 description 1
208000020346 hyperlipoproteinemia Diseases 0.000 description 1
238000005417 image-selected in vivo spectroscopy Methods 0.000 description 1
125000002632 imidazolidinyl group Chemical group 0.000 description 1
125000002636 imidazolinyl group Chemical group 0.000 description 1
125000002883 imidazolyl group Chemical group 0.000 description 1
208000026278 immune system disease Diseases 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
125000001041 indolyl group Chemical group 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
206010022000 influenza Diseases 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
206010022437 insomnia Diseases 0.000 description 1
238000012739 integrated shape imaging system Methods 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000007915 intraurethral administration Methods 0.000 description 1
239000011630 iodine Substances 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
125000002346 iodo group Chemical group I* 0.000 description 1
239000003456 ion exchange resin Substances 0.000 description 1
229920003303 ion-exchange polymer Polymers 0.000 description 1
229960002198 irbesartan Drugs 0.000 description 1
YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
159000000014 iron salts Chemical class 0.000 description 1
230000000302 ischemic effect Effects 0.000 description 1
125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
238000002955 isolation Methods 0.000 description 1
125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
125000001786 isothiazolyl group Chemical group 0.000 description 1
239000000644 isotonic solution Substances 0.000 description 1
239000007951 isotonicity adjuster Substances 0.000 description 1
125000003965 isoxazolidinyl group Chemical group 0.000 description 1
125000000842 isoxazolyl group Chemical group 0.000 description 1
208000011379 keloid formation Diseases 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
229940099563 lactobionic acid Drugs 0.000 description 1
239000008101 lactose Substances 0.000 description 1
208000036546 leukodystrophy Diseases 0.000 description 1
238000011694 lewis rat Methods 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
230000004322 lipid homeostasis Effects 0.000 description 1
230000008604 lipoprotein metabolism Effects 0.000 description 1
229960002394 lisinopril Drugs 0.000 description 1
CZRQXSDBMCMPNJ-ZUIPZQNBSA-N lisinopril dihydrate Chemical compound O.O.C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 CZRQXSDBMCMPNJ-ZUIPZQNBSA-N 0.000 description 1
229940040692 lithium hydroxide monohydrate Drugs 0.000 description 1
GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 1
229910003002 lithium salt Inorganic materials 0.000 description 1
159000000002 lithium salts Chemical class 0.000 description 1
239000002171 loop diuretic Substances 0.000 description 1
229960004773 losartan Drugs 0.000 description 1
KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 1
229960004844 lovastatin Drugs 0.000 description 1
PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
235000015263 low fat diet Nutrition 0.000 description 1
235000004213 low-fat Nutrition 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
229960003646 lysine Drugs 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
239000001630 malic acid Substances 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
229960002510 mandelic acid Drugs 0.000 description 1
150000002696 manganese Chemical class 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
235000013622 meat product Nutrition 0.000 description 1
239000002609 medium Substances 0.000 description 1
229950004994 meglitinide Drugs 0.000 description 1
210000004175 meibomian gland Anatomy 0.000 description 1
208000030159 metabolic disease Diseases 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
229960003105 metformin Drugs 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
VKQFCGNPDRICFG-UHFFFAOYSA-N methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1C1=CC=CC=C1[N+]([O-])=O VKQFCGNPDRICFG-UHFFFAOYSA-N 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
NQMRYBIKMRVZLB-UHFFFAOYSA-N methylamine hydrochloride Chemical compound [Cl-].[NH3+]C NQMRYBIKMRVZLB-UHFFFAOYSA-N 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
229960002237 metoprolol Drugs 0.000 description 1
AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 description 1
229950009116 mevastatin Drugs 0.000 description 1
BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 description 1
PZRHRDRVRGEVNW-UHFFFAOYSA-N milrinone Chemical compound N1C(=O)C(C#N)=CC(C=2C=CN=CC=2)=C1C PZRHRDRVRGEVNW-UHFFFAOYSA-N 0.000 description 1
229960003574 milrinone Drugs 0.000 description 1
210000003470 mitochondria Anatomy 0.000 description 1
201000011540 mitochondrial DNA depletion syndrome 4a Diseases 0.000 description 1
230000002438 mitochondrial effect Effects 0.000 description 1
238000002156 mixing Methods 0.000 description 1
229960005170 moexipril Drugs 0.000 description 1
150000004682 monohydrates Chemical class 0.000 description 1
125000002757 morpholinyl group Chemical group 0.000 description 1
238000010172 mouse model Methods 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
PLWAKFARFCNHJO-UHFFFAOYSA-N n-methylpyridine-4-carboxamide Chemical compound CNC(=O)C1=CC=NC=C1 PLWAKFARFCNHJO-UHFFFAOYSA-N 0.000 description 1
125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
VWPOSFSPZNDTMJ-UCWKZMIHSA-N nadolol Chemical compound C1[C@@H](O)[C@@H](O)CC2=C1C=CC=C2OCC(O)CNC(C)(C)C VWPOSFSPZNDTMJ-UCWKZMIHSA-N 0.000 description 1
229960004255 nadolol Drugs 0.000 description 1
KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
201000003631 narcolepsy Diseases 0.000 description 1
OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 description 1
229960000698 nateglinide Drugs 0.000 description 1
PKWDZWYVIHVNKS-UHFFFAOYSA-N netoglitazone Chemical compound FC1=CC=CC=C1COC1=CC=C(C=C(CC2C(NC(=O)S2)=O)C=C2)C2=C1 PKWDZWYVIHVNKS-UHFFFAOYSA-N 0.000 description 1
230000004770 neurodegeneration Effects 0.000 description 1
208000015122 neurodegenerative disease Diseases 0.000 description 1
229960001783 nicardipine Drugs 0.000 description 1
BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
229960001597 nifedipine Drugs 0.000 description 1
229960000715 nimodipine Drugs 0.000 description 1
229960000227 nisoldipine Drugs 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
235000021590 normal diet Nutrition 0.000 description 1
230000000414 obstructive effect Effects 0.000 description 1
125000005060 octahydroindolyl group Chemical group N1(CCC2CCCCC12)* 0.000 description 1
125000005061 octahydroisoindolyl group Chemical group C1(NCC2CCCCC12)* 0.000 description 1
229960002446 octanoic acid Drugs 0.000 description 1
229960002969 oleic acid Drugs 0.000 description 1
XDUHQPOXLUAVEE-BPMMELMSSA-N oleoyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CCCCCCC\C=C/CCCCCCCC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 XDUHQPOXLUAVEE-BPMMELMSSA-N 0.000 description 1
LVRLSYPNFFBYCZ-VGWMRTNUSA-N omapatrilat Chemical compound C([C@H](S)C(=O)N[C@H]1CCS[C@H]2CCC[C@H](N2C1=O)C(=O)O)C1=CC=CC=C1 LVRLSYPNFFBYCZ-VGWMRTNUSA-N 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
229960001243 orlistat Drugs 0.000 description 1
AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
229960005010 orotic acid Drugs 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
201000008482 osteoarthritis Diseases 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
229940116315 oxalic acid Drugs 0.000 description 1
125000000160 oxazolidinyl group Chemical group 0.000 description 1
125000002971 oxazolyl group Chemical group 0.000 description 1
125000005476 oxopyrrolidinyl group Chemical group 0.000 description 1
125000004430 oxygen atom Chemical group O* 0.000 description 1
229940098695 palmitic acid Drugs 0.000 description 1
QBYOCCWNZAOZTL-MDMKAECGSA-N palmitoleoyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CCCCCCC\C=C/CCCCCC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 QBYOCCWNZAOZTL-MDMKAECGSA-N 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000008188 pellet Substances 0.000 description 1
235000019371 penicillin G benzathine Nutrition 0.000 description 1
229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
125000004344 phenylpropyl group Chemical group 0.000 description 1
239000011574 phosphorus Substances 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
SIOXPEMLGUPBBT-UHFFFAOYSA-M picolinate Chemical compound [O-]C(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-M 0.000 description 1
229940081066 picolinic acid Drugs 0.000 description 1
229960005095 pioglitazone Drugs 0.000 description 1
125000004193 piperazinyl group Chemical group 0.000 description 1
XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical compound O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 description 1
125000003386 piperidinyl group Chemical group 0.000 description 1
229960002797 pitavastatin Drugs 0.000 description 1
VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 description 1
229920000768 polyamine Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000002952 polymeric resin Substances 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
239000008057 potassium phosphate buffer Substances 0.000 description 1
159000000001 potassium salts Chemical class 0.000 description 1
WSHYKIAQCMIPTB-UHFFFAOYSA-M potassium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [K+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 WSHYKIAQCMIPTB-UHFFFAOYSA-M 0.000 description 1
229960002965 pravastatin Drugs 0.000 description 1
TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
201000009104 prediabetes syndrome Diseases 0.000 description 1
201000000484 premenstrual tension Diseases 0.000 description 1
238000012746 preparative thin layer chromatography Methods 0.000 description 1
150000003141 primary amines Chemical class 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
229960004919 procaine Drugs 0.000 description 1
NPUSXSOBPNHOPH-UHFFFAOYSA-N propan-2-yl 4-(2-chlorophenyl)-1-ethyl-2-methyl-5-oxo-4,7-dihydrofuro[3,4-b]pyridine-3-carboxylate Chemical compound CC(C)OC(=O)C1=C(C)N(CC)C(COC2=O)=C2C1C1=CC=CC=C1Cl NPUSXSOBPNHOPH-UHFFFAOYSA-N 0.000 description 1
125000006410 propenylene group Chemical group 0.000 description 1
235000019260 propionic acid Nutrition 0.000 description 1
229960003712 propranolol Drugs 0.000 description 1
208000020016 psychiatric disease Diseases 0.000 description 1
230000001107 psychogenic effect Effects 0.000 description 1
125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
150000003212 purines Chemical class 0.000 description 1
125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
125000003373 pyrazinyl group Chemical group 0.000 description 1
125000003072 pyrazolidinyl group Chemical group 0.000 description 1
125000003226 pyrazolyl group Chemical group 0.000 description 1
125000002098 pyridazinyl group Chemical group 0.000 description 1
125000004076 pyridyl group Chemical group 0.000 description 1
125000000714 pyrimidinyl group Chemical group 0.000 description 1
125000000719 pyrrolidinyl group Chemical group 0.000 description 1
125000000168 pyrrolyl group Chemical group 0.000 description 1
229940107700 pyruvic acid Drugs 0.000 description 1
JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 description 1
229960001455 quinapril Drugs 0.000 description 1
125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
229960002354 repaglinide Drugs 0.000 description 1
230000010076 replication Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
208000037803 restenosis Diseases 0.000 description 1
230000004141 reverse cholesterol transport Effects 0.000 description 1
230000006965 reversible inhibition Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
229960004586 rosiglitazone Drugs 0.000 description 1
229960000672 rosuvastatin Drugs 0.000 description 1
BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 1
229960004889 salicylic acid Drugs 0.000 description 1
229950001780 sampatrilat Drugs 0.000 description 1
235000003441 saturated fatty acids Nutrition 0.000 description 1
150000004671 saturated fatty acids Chemical class 0.000 description 1
201000000980 schizophrenia Diseases 0.000 description 1
208000010157 sclerosing cholangitis Diseases 0.000 description 1
238000007423 screening assay Methods 0.000 description 1
229940116353 sebacic acid Drugs 0.000 description 1
210000002374 sebum Anatomy 0.000 description 1
230000028327 secretion Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
229960002855 simvastatin Drugs 0.000 description 1
201000009890 sinusitis Diseases 0.000 description 1
MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 description 1
229960004034 sitagliptin Drugs 0.000 description 1
230000009759 skin aging Effects 0.000 description 1
208000019116 sleep disease Diseases 0.000 description 1
AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
239000011734 sodium Substances 0.000 description 1
235000015424 sodium Nutrition 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000008137 solubility enhancer Substances 0.000 description 1
238000003797 solvolysis reaction Methods 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
ZBMZVLHSJCTVON-UHFFFAOYSA-N sotalol Chemical compound CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ZBMZVLHSJCTVON-UHFFFAOYSA-N 0.000 description 1
229960002370 sotalol Drugs 0.000 description 1
ZPKJBVIFUSGFLJ-UHFFFAOYSA-N spiro[3,4-dihydrochromene-2,4'-piperidine]-1'-carboxamide Chemical compound N1(CCC2(CC1)OC1=CC=CC=C1CC2)C(=O)N ZPKJBVIFUSGFLJ-UHFFFAOYSA-N 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
229960004274 stearic acid Drugs 0.000 description 1
125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
230000007863 steatosis Effects 0.000 description 1
239000012258 stirred mixture Substances 0.000 description 1
125000003107 substituted aryl group Chemical group 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
229920003002 synthetic resin Polymers 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
229960001367 tartaric acid Drugs 0.000 description 1
229960005187 telmisartan Drugs 0.000 description 1
230000028016 temperature homeostasis Effects 0.000 description 1
ROUYFJUVMYHXFJ-UHFFFAOYSA-N tert-butyl 4-oxopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(=O)CC1 ROUYFJUVMYHXFJ-UHFFFAOYSA-N 0.000 description 1
XPSOOGPODJERSO-UHFFFAOYSA-N tert-butyl 6-fluoro-4-hydroxyspiro[3,4-dihydrochromene-2,4'-piperidine]-1'-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC21OC1=CC=C(F)C=C1C(O)C2 XPSOOGPODJERSO-UHFFFAOYSA-N 0.000 description 1
KBNCFDUTYYMZTG-UHFFFAOYSA-N tert-butyl 7-fluoro-4-hydroxyspiro[3,4-dihydrochromene-2,4'-piperidine]-1'-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC21OC1=CC(F)=CC=C1C(O)C2 KBNCFDUTYYMZTG-UHFFFAOYSA-N 0.000 description 1
ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 1
238000010998 test method Methods 0.000 description 1
150000004685 tetrahydrates Chemical class 0.000 description 1
125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
229960004559 theobromine Drugs 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
231100001274 therapeutic index Toxicity 0.000 description 1
150000001467 thiazolidinediones Chemical class 0.000 description 1
125000001984 thiazolidinyl group Chemical group 0.000 description 1
125000001544 thienyl group Chemical group 0.000 description 1
229960004605 timolol Drugs 0.000 description 1
125000003944 tolyl group Chemical group 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
239000012049 topical pharmaceutical composition Substances 0.000 description 1
229960005461 torasemide Drugs 0.000 description 1
231100000816 toxic dose Toxicity 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
230000009466 transformation Effects 0.000 description 1
238000011830 transgenic mouse model Methods 0.000 description 1
201000010875 transient cerebral ischemia Diseases 0.000 description 1
125000004665 trialkylsilyl group Chemical group 0.000 description 1
125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
150000004684 trihydrates Chemical class 0.000 description 1
125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
125000005455 trithianyl group Chemical group 0.000 description 1
125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 1
229960001641 troglitazone Drugs 0.000 description 1
GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 1
229960004418 trolamine Drugs 0.000 description 1
229960000281 trometamol Drugs 0.000 description 1
229910052721 tungsten Inorganic materials 0.000 description 1
229960002703 undecylenic acid Drugs 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
230000002792 vascular Effects 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
SYOKIDBDQMKNDQ-XWTIBIIYSA-N vildagliptin Chemical compound C1C(O)(C2)CC(C3)CC1CC32NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-XWTIBIIYSA-N 0.000 description 1
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
238000009736 wetting Methods 0.000 description 1
229940051021 yellow-fever virus Drugs 0.000 description 1
150000003751 zinc Chemical class 0.000 description 1